CCM
Concord Medical Services Holdings Ltd
$4.78
0.00%
$20.8M
No data for this timeframe.
Vol
Market Cap$20.8M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$386.00
Inst. Activity0 buys / 1 sells
SEC Reports2
Exchange NYSE·Sector Services-Offices & Clinics of Doctors of Medicine·Inc. E9·CIK 0001472072·Prev Close $4.78
Recent Activity
May 18, 2026
SEC
Concord Medical Services Holdings Ltd filed a 6-K reporting that Mr. Liang Chang resigned as an executive director of it
6-K — Impact 4/10
May 13, 2026
SEC
Concord Medical Services Holdings Ltd filed a 6-K reporting changes to the board of directors of its subsidiary Concord
6-K — Impact 2/10
Inst.
UBS Group AG — TRIM
37,848 shares ($232.4K)
Inst.
UBS Group AG — DOUBLED
67,919 shares ($389.2K)
Analyst Ratings
0Strong Buy
0Buy
2Hold
5Sell
1Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Nov 23, 2012 | Morgan Stanley | MAINTAIN | Overweight |
| Jul 6, 2012 | Morgan Stanley | MAINTAIN | Overweight |
| Mar 22, 2012 | JP Morgan | MAINTAIN | Overweight |
Latest Reports
NEUTRAL
6-K
4/10
Concord Medical Services Holdings Ltd filed a 6-K reporting that Mr. Liang Chang resigned as an executive director of it
May 18, 2026
NEUTRAL
6-K
2/10
Concord Medical Services Holdings Ltd filed a 6-K reporting changes to the board of directors of its subsidiary Concord
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $386.00 | — |
1 institutional holders with $386.00 total value (100 shares) as of 2025-Q4. Top holders: MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 100 | $386.00 | 100.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | TRIM | 67,919 | 37,848 | -44.3% | $232.4K | 2025-Q3 |
| UBS Group AG | DOUBLED | 217 | 67,919 | +31199.1% | $389.2K | 2025-Q2 |
| UBS Group AG | TRIM | 659 | 217 | -67.1% | $868.00 | 2025-Q1 |
| UBS Group AG | TRIM | 923 | 659 | -28.6% | $3.5K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Nov 2012): 0% buy across 8 analysts — 0 strong buy, 0 buy, 2 hold, 5 sell, 1 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2020-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Nov 23, 2012 | Morgan Stanley | MAINTAIN | — | Overweight |
| Jul 6, 2012 | Morgan Stanley | MAINTAIN | — | Overweight |
| Mar 22, 2012 | JP Morgan | MAINTAIN | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Dec 1, 2021 | 0 | 0 | 2 | 5 | 1 | 0% | |
| Nov 1, 2021 | 0 | 0 | 2 | 5 | 1 | 0% | |
| Oct 1, 2021 | 0 | 0 | 2 | 5 | 1 | 0% | |
| Sep 1, 2021 | 0 | 0 | 2 | 5 | 1 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.